|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jung M, Shin SJ, Koom WS, Jung I, Keum KC,
Hur H, Min BS, Baik SH, Kim NK, Kim H, et al: A randomized phase 2
study of neoadjuvant chemoradiaton therapy with
5-fluorouracil/leucovorin or irinotecan/S-1 in patients with
locally advanced rectal cancer. Int J Radiat Oncol Biol Phys.
93:1015–1022. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jang HJ, Kim BJ, Kim JH and Kim HS: The
addition of bevacizumab in the first-line treatment for metastatic
colorectal cancer: An updated meta-analysis of randomized trials.
Oncotarget. 8:73009–73016. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Freeman K, Connock M, Cummins E, Gurung T,
Taylor-Phillips S, Court R, Saunders M, Clarke A and Sutcliffe P:
Fluorouracil plasma monitoring: systematic review and economic
evaluation of the My5-FU assay for guiding dose adjustment in
patients receiving fluorouracil chemotherapy by continuous
infusion. Health Technol Assess. 19:1–321, v-vi. 2015. View Article : Google Scholar
|
|
5
|
Li W, Jie Z, Li Z, Liu Y, Gan Q, Mao Y and
Wang X: ERCC1 siRNA ameliorates drug resistance to cisplatin in
gastric carcinoma cell lines. Mol Med Rep. 9:2423–2428. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vilmar A and Sørensen JB: Excision repair
cross-complementation group 1 (ERCC1) in platinum-based treatment
of non-small cell lung cancer with special emphasis on carboplatin:
A review of current literature. Lung Cancer. 64:131–139. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Libra M, Navolanic PM, Talamini R, Cecchin
E, Sartor F, Tumolo S, Masier S, Travali S, Boiocchi M and Toffoli
G: Thymidylate synthetase mRNA levels are increased in liver
metastases of colorectal cancer patients resistant to
fluoropyrimidine-based chemotherapy. BMC Cancer. 4:112004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang B, Walsh SJ and Saif MW: Pancytopenia
and severe gastrointestinal toxicities associated with
5-fluorouracil in a patient with thymidylate synthase (TYMS)
polymorphism. Cureus. 8:e7982016.PubMed/NCBI
|
|
9
|
Yasumatsu R, Nakashima T, Uryu H, Ayada T,
Wakasaki T, Kogo R, Masuda M, Fukushima M and Komune S:
Correlations between thymidylate synthase expression and
chemosensitivity to 5-fluorouracil, cell proliferation and clinical
outcome in head and neck squamous cell carcinoma. Chemotherapy.
55:36–41. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hu HB, Kuang L, Zeng XM, Li B, Liu EY and
Zhong MZ: Predictive value of thymidylate synthase expression in
gastric cancer: A systematic review with meta-analysis. Asian Pac J
Cancer Prev. 13:261–267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Terashima M, Irinoda T, Fujiwara H, Nakaya
T, Takagane A, Abe K, Yonezawa H, Oyama K, Inaba T, Saito K, et al:
Roles of thymidylate synthase and dihydropyrimidine dehydrogenase
in tumor progression and sensitivity to 5-fluorouracil in human
gastric cancer. Anticancer Res 22 (2A). 761–768. 2002.
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sobrero A, Guglielmi A, Grossi F, Puglisi
F and Aschele C: Mechanism of action of fluoropyrimidines:
Relevance to the new developments in colorectal cancer
chemotherapy. Semin Oncol. 27 (Suppl 10):72–77. 2000.PubMed/NCBI
|
|
14
|
Stevens EV, Nishizuka S, Antony S, Reimers
M, Varma S, Young L, Munson PJ, Weinstein JN, Kohn EC and Pommier
Y: Predicting cisplatin and trabectedin drug sensitivity in ovarian
and colon cancers. Mol Cancer Ther. 7:10–18. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kozloff M, Yood MU, Berlin J, Flynn PJ,
Kabbinavar FF, Purdie DM, Ashby MA, Dong W, Sugrue MM and Grothey
A; Investigators of the BRiTE study, : Clinical outcomes associated
with bevacizumab-containing treatment of metastatic colorectal
cancer: The BRiTE observational cohort study. Oncologist.
14:862–870. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ahn SJ, Kim JH, Park SJ and Han JK:
Prediction of the therapeutic response after FOLFOX and FOLFIRI
treatment for patients with liver metastasis from colorectal cancer
using computerized CT texture analysis. Eur J Radiol. 85:1867–1874.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Takenaka T, Yoshino I, Kouso H, Ohba T,
Yohena T, Osoegawa A, Shoji F and Maehara Y: Combined evaluation of
Rad51 and ERCC1 expressions for sensitivity to platinum agents in
non-small cell lung cancer. Int J Cancer. 121:895–900. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun S, Shi W, Wu Z, Zhang G, Yang BO and
Jiao S: Prognostic significance of the mRNA expression of ERCC1,
RRM1, TUBB3 and TYMS genes in patients with non-small cell lung
cancer. Exp Ther Med. 10:937–941. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cao Y, Zhang G, Wang P, Zhou J, Gan W,
Song Y, Huang L, Zhang Y, Luo G, Gong J, et al: Clinical
significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1,
TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer. BMC
Gastroenterol. 17:22017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Leng XF, Chen MW, Xian L, Dai L, Ma GY and
Li MH: Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1,
RRM1 and TUBB3 to predict prognosis in patients with non-small cell
lung cancer who received adjuvant chemotherapy. J Exp Clin Cancer
Res. 31:252012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wei J, Zou Z, Qian X, Ding Y, Xie L,
Sanchez JJ, Zhao Y, Feng J, Ling Y, Liu Y, et al: ERCC1 mRNA levels
and survival of advanced gastric cancer patients treated with a
modified FOLFOX regimen. Br J Cancer. 98:1398–1402. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Burdelski C, Strauss C, Tsourlakis MC,
Kluth M, Hube-Magg C, Melling N, Lebok P, Minner S, Koop C, Graefen
M, et al: Overexpression of thymidylate synthase (TYMS) is
associated with aggressive tumor features and early PSA recurrence
in prostate cancer. Oncotarget. 6:8377–8387. 2015. View Article : Google Scholar : PubMed/NCBI
|
